Products and methods for treating muscular dystrophy
U7snRNA vectors targeting exons 6, 7, and 9 in the DMD gene restore the reading frame, enhancing dystrophin expression and improving muscle function in patients with muscular dystrophy.
JP7948958B2Active Publication Date: 2026-11-11RES INST AT NATIONWIDE CHILDRENS HOSPITAL
Patent Information
- Application Number
- JP2023564657
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2021-04-23
- Filing Date
- 2022-04-22
- Publication Date
- 2026-11-11
- Estimated Expiration
- 2042-04-22
Smart Images

Figure 0007948958000009 
Figure 0007948958000010 
Figure 0007948958000011
Abstract
Products and methods are provided for treating or preventing muscular dystrophy in patients with mutations in any of exons 6, 7, 8, or 9 in the DMD gene. Gene therapy vectors, such as adeno-associated virus (AAV) vectors, and methods of using these vectors to deliver nucleic acids containing DMD antisense sequences in modulating or restoring expression of the transcript of the DMD gene and a functional form of the dystrophin protein, are provided. The products and methods are used to treat, ameliorate, and / or prevent muscular dystrophy, such as Duchenne muscular dystrophy or Becker muscular dystrophy.
Need to check novelty before this filing date? Find Prior Art
Citation Information
Patent Citations
US90,3710-37141993
Antisense oligonucleotides for inducing exon skipping and methods of use thereof
WO2006000057A1
Compositions and methods for correcting dystrophin mutations in human cardiomyocytes
WO2019152609A1
Exon 44-targeted nucleic acids and recombinant adeno-associated virus comprising said nucleic acids for treatment of dystrophin-based myopathies
WO2021026075A1
